PhRMA
JUNE 16, 2023
This June marks Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride Month. At PhRMA, we’re proud to celebrate the diversity and inclusion of our LGBTQ+ colleagues and the patients our companies aim to help. As an industry driven by science, we believe diversity in the lab drives greater collaboration, scientific advancement and groundbreaking medicines impacting the lives of patients.
Drug Topics
JUNE 16, 2023
Melody L. Berg, PharmD, MPH, BCPS, editorial director, American Society of Health-System Pharmacists, explains best practices, treatments, and preventive measures for sunburn, bug bites, and waterborne infections.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PhRMA
JUNE 16, 2023
Policymakers and the media have been taking a close look at the medical supply chain recently, including the manufacturing locations of active pharmaceutical ingredients (APIs) for medicines used by Americans. APIs are what make a medicine a medicine — they are the substance in the medicine that treats or cures a disease or affects a condition within the body.
Drug Topics
JUNE 16, 2023
Hesitation from patients and providers to switch to an infliximab biosimilar may not be necessary, new study finds.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaVoice
JUNE 16, 2023
Industry execs give voice to the “game changers” they believe would have the greatest impact on the healthcare ecosystem for all.
Drug Topics
JUNE 16, 2023
The expanded labeling allows for an intravenously delivered formulation of ibuprofen (Caldolor) in infants aged 3 to 6 months.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
JUNE 16, 2023
According to Dermavant, tapinarof cream 1% is a novel, aryl hydrocarbon receptor agonist in development as a once-daily topical cream.
Pharmacy Times
JUNE 16, 2023
Adult and maternal RSV vaccines reveal positive findings.
PharmaVoice
JUNE 16, 2023
From implementation of the Inflation Reduction Act, to the looming patent cliff and more, pharma leaders have a lot on their plates.
Pharmacy Times
JUNE 16, 2023
Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
JUNE 16, 2023
With the release of ChatGPT, what had long been science fiction became a reality, leaving healthcare wondering where medicine meets machine. | This week, Stanford Medicine and Stanford Institute for Human-Centered Artificial Intelligence (HAI) launched Responsible AI for Safe and Equitable Health (RAISE-Health) with the goal of addressing critical ethical and safety issues regarding the technology.
Pharmacy Times
JUNE 16, 2023
Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.
Fierce Pharma
JUNE 16, 2023
In the battle for superiority in the field of next-gen diabetes and obesity treatments, Novo Nordisk holds the lead as the developer of the metabolism-regulating treatment semaglutide. | In the battle for diabetes and obesity superiority, Novo Nordisk holds a head start as the original developer of the metabolism-regulating treatment semaglutide. But Eli Lilly is quickly gaining ground and is primed to become the market leader with its GLP-1 treatment Mounjaro, according to GlobalData.
Pharmacy Times
JUNE 16, 2023
Health care professionals can provide patients with tips on appropriate hand sanitizer use, as well as product recommendations.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
JUNE 16, 2023
Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured an unusual sentiment: optimism inflected with worry. Optimism because, after years of failed studies and the disastrous accelerated approval of aducanumab, we’re enjoying a less than one-year-old streak of good news. The latest bright flash is the June 9 Food and Drug Administration hearing on the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi).
Pharmacy Times
JUNE 16, 2023
Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.
pharmaphorum
JUNE 16, 2023
How digital transformation can revamp product and process visibility Mike.
Pharmacy Times
JUNE 16, 2023
A plethora of targeted therapies, biomarker-driven therapies, and immunotherapies are now available.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JUNE 16, 2023
Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. | After scoring accelerated approval to treat HER2-positive stomach cancer in 2021, the drug has now shown it can stave off tumor progression in patients with PD-L1 positive tumors.
Pharmacy Times
JUNE 16, 2023
Claire Biermaas, president of Corporate Partnerships at AmerisourceBergen, discussed the Corporate Partnerships Team, which works closely with pharmacy customers to guide their processes and help execute their vision.
Fierce Healthcare
JUNE 16, 2023
Luma Health, a platform automating the patient journey, has launched a new digital call deflection service to reduce inbound call volume for provider staff. | Calls are redirected to self-service text messaging, which the company argues helps short-staffed providers get patients to the next step in their care quickly.
Pharmacy Times
JUNE 16, 2023
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.
Fierce Pharma
JUNE 16, 2023
Less than a month after AbbVie and Genmab won FDA approval for Epkinly, Roche has crossed the finish line with its bispecific answer to large B-cell lymphoma. | Less than a month after AbbVie and Genmab won FDA approval for Epkinly, Roche has crossed the finish line with its bispecific answer to large B-cell lymphoma, though with a narrower label.
Pharmacy Times
JUNE 16, 2023
Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.
STAT
JUNE 16, 2023
This year, nearly 6 million dogs in the U.S. will receive a cancer diagnosis. That’s approximately three times greater than the number of Americans who will be diagnosed with cancer this year, even though humans are estimated to outnumber pet dogs by nearly 4 to 1. Yet the genetic similarities between human and dog cancers may point the way to treatments that can save lives on both ends of the leash.
Pharmacy Times
JUNE 16, 2023
VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.
Drug Store News
JUNE 16, 2023
The nail category is taking a skin care-level approach when it comes to seasonal trends.
STAT
JUNE 16, 2023
Testosterone supplementation in men with low levels of the hormone did not increase the risk of heart attacks in a 5,246-patient study, allaying fears that were raised more than a decade ago in a smaller trial, researchers said Friday. Although the results ease a significant safety concern about testosterone-containing gels and patches, the researchers running the study emphasized it does not address the more widespread use of such products in men who have normal levels of testosterone but who h
Pharmaceutical Technology
JUNE 16, 2023
France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs). The developer has tested OVX836 in four completed clinical trials.
STAT
JUNE 16, 2023
The policy that the American Medical Association adopted this week to de-emphasize the use of BMI is part of a growing movement away from the single, weight-based metric and toward a broader way of assessing health risk through multiple factors. Yet it will take more than the giant physician group to displace the use of the body mass index throughout medicine.
Drug Store News
JUNE 16, 2023
Chobani Zero Sugar Drinks are available in mixed berry, peaches and cream, strawberry cheesecake and milk and cookies flavors.
pharmaphorum
JUNE 16, 2023
Cala launches wearable to treat hand tremor in Parkinson's Phil.
STAT
JUNE 16, 2023
Racial bias is everywhere in medicine, including the calculators doctors commonly use to predict a patient’s risk of disease and inform their treatment. A growing movement is encouraging medical specialties and hospitals to reconsider the use of race in those tools. But a new study shows that removing bias isn’t as simple as taking race out of the equation.
Expert insights. Personalized for you.
263 
Let's personalize your content